Fertility preservation after chemotherapy for Hodgkin lymphoma

Hematological Oncology

Volumn 28, Issue 4, 2010, Pages 168-179

  Van Der Kaaij, Marleen A E ^a   Van Echten Arends, Jannie ^a   Simons, Arnold H M ^a   Kluin Nelemans, Hanneke C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Chemotherapy; Fertility; Fertility preservation; GnRH analogues; Hodgkin lymphoma; Spermatogenesis

Indexed keywords

BLEOMYCIN; BUSULFAN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; GONADORELIN; IFOSFAMIDE; LOMUSTINE; MELPHALAN; PROCARBAZINE; VINBLASTINE;

AZOOSPERMIA; CHEMOTHERAPY; CRYOPRESERVATION; EXPERIMENTATION; FEMALE; FEMALE FERTILITY; FERTILIZATION IN VITRO; FOLLOW UP; GONAD FUNCTION; HODGKIN DISEASE; HUMAN; INFERTILITY; MALE; MALE FERTILITY; MENOPAUSE; OLIGOSPERMIA; OOCYTE DEVELOPMENT; OVARY INSUFFICIENCY; PRIORITY JOURNAL; REVIEW; RISK; TISSUE PRESERVATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZOOSPERMIA; CRYOPRESERVATION; FEMALE; FERTILITY; HODGKIN DISEASE; HUMANS; MALE; OVARIAN DISEASES;

EID: 78649494392     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.939     Document Type: Review

References (129)

1. Raemaekers JMM, Lugtenburg PJ. Het Hodgkinlymfoom. In Handboek hematologie (1st edn), Löwenberg B, Ossenkoppele GJ, de Witte T, Boogaerts MA (eds). De Tijdstroom: Utrecht, 2008; 391-403.
2. Klein CE. Gonadal complications. In Cancer Medicine (7th edn), Kufe DW, Bast RC, Hait WN, Hong WK, Pollock RE, Weichselbaum RR, Holland JF, Frei E III, (eds). BC Decker Inc.: Hamilton, Ontario, 2006; 2194-2203.
3. Howell SJ, Shalet SM. Spermatogenesis after cancer treatment: damage and recovery. J Natl Cancer Inst Monogr 2005; 2005: 12-17.
4. Ash P. The influence of radiation on fertility in man. Br J Radiol 1980; 53: 271-278.
5. Meistrich ML, Wilson G, Mathur K, et al. Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin's disease. J Clin Oncol 1997; 15: 3488-3495.
6. Trottmann M, Becker AJ, Stadler T, et al. Semen quality in men with malignant diseases before and after therapy and the role of cryopreservation. Eur Urol 2007; 52: 355-367.
7. Schrader M, Muller M, Straub B, Miller K. The impact of chemotherapy on male fertility: a survey of the biologic basis and clinical aspects. Reprod Toxicol 2001; 15: 611-617.
8. Shetty G, Meistrich ML. Hormonal approaches to preservation and restoration of male fertility after cancer treatment. J Natl Cancer Inst Monogr 2005; 2005: 36-39.
9. Browne H, Norian JM, Feinberg EC, Decherney AH, Armstrong AY. Gonadal dysfunction. In Cancer: Principles and Practice of Oncology (8th edn), DeVita VT, Lawrence TS, Rosenberg SA (eds). Lippincott Williams & Wilkins: Philadelphia, 2008; 2692-2710.
10. van der Kaaij MA, Heutte N, Le Stang N, et al. Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007; 25: 2825-2832.
11. Meistrich ML, Wilson G, Brown BW, da Cunha MF, Lipshultz LI. Impact of cyclophosphamide on long-term reduction in sperm count in men treated with combination chemotherapy for Ewing and soft tissue sarcomas. Cancer 1992; 70: 2703-2712.
12. Howell SJ, Radford JA, Adams JE, Smets EM, Warburton R, Shalet SM. Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy. Clin Endocrinol (Oxf) 2001; 55: 315-324.
13. Schilsky RL, Lewis BJ, Sherins RJ, Young RC. Gonadal dysfunction in patients receiving chemotherapy for cancer. Ann Intern Med 1980; 93: 109-114.
14. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996; 14: 1718-1729.
15. Familiari G, Caggiati A, Nottola SA, Ermini M, Di Benedetto MR, Motta PM. Ultrastructure of human ovarian primordial follicles after combination chemotherapy for Hodgkin's disease. Hum Reprod 1993; 8: 2080-2087.
16. Falcone T, Attaran M, Bedaiwy MA, Goldberg JM. Ovarian function preservation in the cancer patient. Fertil Steril 2004; 81: 243-257.
17. van der Kaaij MAE, Heutte N, van Echten-Arends J, et al. Sperm quality before treatment in patients with early stage Hodgkin lymphoma enrolled in EORTC-GELA Lymphoma Group trials. Haematologica 2009; 94: 1691-1697.
18. Rueffer U, Breuer K, Josting A, et al. Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment. Ann Oncol 2001; 12: 1307-1311.
19. Gandini L, Lombardo F, Salacone P, et al. Testicular cancer and Hodgkin's disease: evaluation of semen quality. Hum Reprod 2003; 18: 796-801.
20. Fossa SD, Theodorsen L, Norman N, Aabyholm T. Recovery of impaired pretreatment spermatogenesis in testicular cancer. Fertil Steril 1990; 54: 493-496.
21. Sieniawski M, Reineke T, Josting A, et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Ann Oncol 2008; 19: 1795-1801.
22. Viviani S, Ragni G, Santoro A, et al. Testicular dysfunction in Hodgkin's disease before and after treatment. Eur J Cancer 1991; 27: 1389-1392.
23. Kiserud CE, Fossa A, Holte H, Fossa SD. Post-treatment parenthood in Hodgkin's lymphoma survivors. Br J Cancer 2007; 96: 1442-1449.
24. Aisner J, Wiernik PH, Pearl P. Pregnancy outcome in patients treated for Hodgkin's disease. J Clin Oncol 1993; 11: 507-512.
25. Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol 1986; 67: 604-606.
26. Haukvik UK, Dieset I, Bjoro T, Holte H, Fossa SD. Treatment-related premature ovarian failure as a long-term complication after Hodgkin's lymphoma. Ann Oncol 2006; 17: 1428-1433.
27. De Bruin ML, Huisbrink J, Hauptmann M, et al. Treatment-related risk factors for premature menopause following Hodgkin's lymphoma. Blood 2008; 111: 101-108.
28. Behringer K, Breuer K, Reineke T, et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2005; 23: 7555-7564.
29. Hodgson DC, Pintilie M, Gitterman L, et al. Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematol Oncol 2007; 25: 11-15.
30. Magelssen H, Haugen TB, von D V, Melve KK, Sandstad B, Fossa SD. Twenty years experience with semen cryopreservation in testicular cancer patients: who needs it? Eur Urol 2005; 48: 779-785.
31. Blackhall FH, Atkinson AD, Maaya MB, et al. Semen cryopreservation, utilisation and reproductive outcome in men treated for Hodgkin's disease. Br J Cancer 2002; 87: 381-384.
32. van Casteren NJ, van Santbrink EJ, van IW, Romijn JC, Dohle GR. Use rate and assisted reproduction technologies outcome of cryopreserved semen from 629 cancer patients. Fertil Steril 2008; 90: 2245-2250.
33. Agarwal A, Ranganathan P, Kattal N, et al. Fertility after cancer: a prospective review of assisted reproductive outcome with banked semen specimens. Fertil Steril 2004; 81: 342-348.
34. Chung K, Irani J, Knee G, Efymow B, Blasco L, Patrizio P. Sperm cryopreservation for male patients with cancer: an epidemiological analysis at the University of Pennsylvania. Eur J Obstet Gynecol Reprod Biol 2004; 113: S7-S11.
35. O'Flaherty C, Vaisheva F, Hales BF, Chan P, Robaire B. Characterization of sperm chromatin quality in testicular cancer and Hodgkin's lymphoma patients prior to chemotherapy. Hum Reprod 2008; 23: 1044-1052.
36. Hourvitz A, Goldschlag DE, Davis OK, Gosden LV, Palermo GD, Rosenwaks Z. Intracytoplasmic sperm injection (ICSI) using cryopreserved sperm from men with malignant neoplasm yields high pregnancy rates. Fertil Steril 2008; 90: 557-563.
37. Hibi H, Ohori T, Yamada Y, Honda N, Hashiba Y, Asada Y. Testicular sperm extraction and ICSI in patients with post-chemotherapy non-obstructive azoospermia. Arch Androl 2007; 53: 63-65.
38. Meacham RB. Testicular sperm retrieval in the management of chemotherapy induced azoospermia. J Androl 2003; 24: 807.
39. Ward JA, Robinson J, Furr BJ, Shalet SM, Morris ID. Protection of spermatogenesis in rats from the cytotoxic procarbazine by the depot formulation of Zoladex, a gonadotropin-releasing hormone agonist. Cancer Res 1990; 50: 568-574.
40. Meistrich ML, Parchuri N, Wilson G, Kurdoglu B, Kangasniemi M. Hormonal protection from cyclophosphamide-induced inactivation of rat stem spermatogonia. J Androl 1995; 16: 334-341.
41. Udagawa K, Ogawa T, Watanabe T, Yumura Y, Takeda M, Hosaka M. GnRH analog, leuprorelin acetate, promotes regeneration of rat spermatogenesis after severe chemical damage. Int J Urol 2001; 8: 615-622.
42. Ataya K, Rao LV, Lawrence E, Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 1995; 52: 365-372.
43. Masala A, Faedda R, Alagna S, et al. Use of testosterone to prevent cyclophosphamide-induced azoospermia. Ann Intern Med 1997; 126: 292-295.
44. Brennemann W, Brensing KA, Leipner N, Boldt I, Klingmuller D. Attempted protection of spermatogenesis from irradiation in patients with seminoma by D-Tryptophan-6 luteinizing hormone releasing hormone. Clin Investig 1994; 72: 838-842.
45. Kreuser ED, Hetzel WD, Hautmann R, Pfeiffer EF. Reproductive toxicity with and without LHRHA administration during adjuvant chemotherapy in patients with germ cell tumors. Horm Metab Res 1990; 22: 494-498.
46. Krause W, Pfluger KH. Treatment with the gonadotropin-releasinghormone agonist buserelin to protect spermatogenesis against cytotoxic treatment in young men. Andrologia 1989; 21: 265-270.
47. Fossa SD, Klepp O, Norman N. Lack of gonadal protection by medroxyprogesterone acetate-induced transient medical castration during chemotherapy for testicular cancer. Br J Urol 1988; 62: 449-453.
48. Waxman JH, Ahmed R, Smith D, et al. Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother Pharmacol 1987; 19: 159-162.
49. Johnson DH, Linde R, Hainsworth JD, et al. Effect of a luteinizing hormone releasing hormone agonist given during combination chemotherapy on posttherapy fertility in male patients with lymphoma: preliminary observations. Blood 1985; 65: 832-836.
50. Edgar DH, Gook DA. How should the clinical efficiency of oocyte cryopreservation be measured? Reprod BioMed Online 2007; 14: 430-435.
51. Lee SJ, Schover LR, Partridge AH, et al. American society of clinical oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 6 A.D; 24: 2917-2931.
52. Chen C. Pregnancy after human oocyte cryopreservation. Lancet 1986; 1: 884-886.
53. Kuwayama M, Vajta G, Kato O, Leibo SP. Highly efficient vitrification method for cryopreservation of human oocytes. Reprod BioMed Online 2005; 11: 300-308.
54. Barritt J, Luna M, Duke M, et al. Report of four donor-recipient oocyte cryopreservation cycles resulting in high pregnancy and implantation rates. Fertil Steril 2007; 87: 187-189.
55. Noyes N, Porcu E. Borini A. Over 900 oocyte cryopreservation babies born with no apparent increase in congenital anomalies. Reprod BioMed Online 2009; 18: 769-776.
56. Wennerholm UB, Soderstrom-Anttila V, Bergh C, et al. Children born after cryopreservation of embryos or oocytes: a systematic review of outcome data. Hum Reprod 2009; 24: 2158-2172.
57. ASRM. Practice committee response to Rybak and Lieman: elective self-donation of oocytes. Fertil Steril 2009; 92: 1513-1514.
58. Donnez J, Dolmans MM, Demylle D, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 2004; 364: 1405-1410.
59. Meirow D, Levron J, Eldar-Geva T, et al. Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med 2005; 353: 318-321.
60. Demeestere I, Simon P, Emiliani S, Delbaere A, Englert Y, Fertility preservation: successful, transplantation of cryopreserved ovarian tissue in a young patient previously treated for Hodgkin's disease. Oncologist 2007; 12: 1437-1442.
61. Andersen CY, Rosendahl M, Byskov AG, et al. Two successful pregnancies following autotransplantation of frozen/thawed ovarian tissue. Hum Reprod 2008; 23: 2266-2272.
62. Meirow D, Hardan I, Dor J, et al. Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients. Hum Reprod 2008; 23: 1007-1013.
63. Seshadri T, Gook D, Lade S, et al. Lack of evidence of disease contamination in ovarian tissue harvested for cryopreservation from patients with Hodgkin lymphoma and analysis of factors predictive of oocyte yield. Br J Cancer 2006; 94: 1007-1010.
64. Ortin TT, Shostak CA, Donaldson SS. Gonadal status and reproductive function following treatment for Hodgkin's disease in childhood: the Stanford experience. Int J Radiat Oncol Biol Phys 1990; 19: 873-880.
65. Bakchine H, Brauner R, Thibaud E, et al. Chemotherapy and ovarian function. Retrospective analysis in 17 girls treated for malignant tumor or hematologic disease. Arch Fr Pediatr 1986; 43: 611-616.
66. Chapman RM, Sutcliffe SB. Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin's disease. Blood 1981; 58: 849-851.
67. Chapman RM, Sutcliffe SB, Malpas JS. Cytotoxic-induced ovarian failure in women with Hodgkin's disease. I. Hormone function. JAMA 1979; 242: 1877-1881.
68. Whitehead E, Shalet SM, Blackledge G, Todd I, Crowther D, Beardwell CG. The effect of combination chemotherapy on ovarian function in women treated for Hodgkin's disease. Cancer 1983; 52: 988-993.
69. Longhi A, Pignotti E, Versari M, Asta S, Bacci G. Effect of oral contraceptive on ovarian function in young females undergoing neoadjuvant chemotherapy treatment for osteosarcoma. Oncol Rep 2003; 10: 151-155.
70. Oktay K, Sonmezer M, Oktem O, Fox K, Emons G, Bang H. Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury. Oncologist 2007; 12: 1055-1066.
71. Beck-Fruchter R, Weiss A, Shalev E. GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data. Hum Reprod Update 2008; 14: 553-561.
72. Clowse MEB, Behera MA, Anders CK, et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Women's Health 2009; 18: 311-319.
73. Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 2009; 91: 694-697.
74. Sverrisdottir A, Nystedt M, Johansson H, Fornander T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 2009; 117: 561-7.
75. Behringer K, Wildt L, Haverkamp H, Diehl V, Pfistner B, Engert A. Results of the randomised phase II trial for the reduction of ovarian failure with the use of GnRH-analogues and oral contraceptives in young women (18-40 years) treated with intensive chemotherapy for advanced-stage Hodgkin's lymphoma. Haematologica 2007; 92: 63-64.
76. Loverro G, Guarini A, Di Naro E, Giacomantonio L, Lavopa C, Liso V. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology 2007; 12: 141-147.
77. Lee SJ, Schover LR, Partridge AH, et al. American society of clinical oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006; 24: 2917-2931.
78. Rang HP, Dale MM, Ritter JM. Cancer chemotherapy. In Pharmacology (4th edn), Churchill Livingstone: Edinburgh, 1999; 663-684.
79. Lazo JS, Larner JM. Individual antineoplastic drugs. In Human Pharmacology (3rd edn), Brody TM, Larner J, Minneman KP (eds). Mosby: St. Louis, 1998; 599-613.
80. Giwercman A, Petersen PM. Cancer and male infertility. Baillieres Best Pract Res Clin Endocrinol Metab 2000; 14: 453-471.
81. Marmor D, Duyck F. Male reproductive potential after MOPP therapy for Hodgkin's disease: a long-term survey. Andrologia 1995; 27: 99-106.
82. Viviani S, Santoro A, Ragni G, Bonfante V, Bestetti O, Bonadonna G. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABV. Eur J Cancer Clin Oncol 1985; 21: 601-605.
83. Anselmo AP, Cartoni C, Bellantuono P, Maurizi-Enrici R, Aboulkair N, Ermini M. Risk of infertility in patients with Hodgkin's disease treated with ABVD vs MOPP vs ABVD/MOPP. Haematologica 1990; 75: 155-158.
84. Santoro A, Bonadonna G, Valagussa P, et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 1987; 5: 27-37.
85. Koziner B, Myers J, Cirrincione C, et al. Treatment of stages I and II Hodgkin's disease with three different therapeutic modalities. Am J Med 1986; 80: 1067-1078.
86. Specht L, Geisler C, Hansen MM, Skakkebaek NE. Testicular function in young men in long-term remission after treatment for the early stages of Hodgkin's disease. Scand J Haematol 1984; 33: 356-362.
87. Cunningham J, Mauch P, Rosenthal DS, Canellos GP. Long-term complications of MOPP chemotherapy in patients with Hodgkin's disease. Cancer Treat Rep 1982; 66: 1015-1022.
88. Sherins RJ, DeVita VT Jr. Effect of drug treatment for lymphoma on male reproductive capacity. Studies of men in remission after therapy. Ann Intern Med 1973; 79: 216-220.
89. da Cunha MF, Meistrich ML, Fuller LM, et al. Recovery of spermatogenesis after treatment for Hodgkin's disease: limiting dose of MOPP chemotherapy. J Clin Oncol 1984; 2: 571-577.
90. Andrieu JM, Masson D, Fiet J, Gourmel B, Czyglik F, Bernard J. Male fertility in Hodgkin's disease before and after chemotherapy (author's transl). Nouv Presse Med 1981; 10: 2085-2088.
91. DeVita VT Jr. The consequences of the chemotherapy of Hodgkin's disease: The 10th David A. Karnofsky Memorial Lecture. Cancer 1981; 47: 1-13.
92. Whitehead E, Shalet SM, Blackledge G, Todd I, Crowther D, Beardwell CG. The effects of Hodgkin's disease and combination chemotherapy on gonadal function in the adult male. Cancer 1982; 49: 418-422.
93. Waxman JH, Terry YA, Wrigley PF, et al. Gonadal function in Hodgkin's disease: long-term follow-up of chemotherapy. Br Med J (Clin Res Ed) 1982; 285: 1612-1613.
94. King DJ, Ratcliffe MA, Dawson AA, Bennett B, Macgregor JE, Klopper AI. Fertility in young men and women after treatment for lymphoma: a study of a population. J Clin Pathol 1985; 38: 1247-1251.
95. Clark ST, Radford JA, Crowther D, Swindell R, Shalet SM. Gonadal function following chemotherapy for Hodgkin's disease: a comparative study of MVPP and a seven-drug hybrid regimen. J Clin Oncol 1995; 13: 134-139.
96. Chapman RM, Sutcliffe SB, Rees LH, Edwards CR, Malpas JS. Cyclical combination chemotherapy and gonadal function. Retrospective study in males. Lancet 1979; 1: 285-289.
97. Kader HA, Rostom AY. Follicle stimulating hormone levels as a predictor of recovery of spermatogenesis following cancer therapy. Clin Oncol (R Coll Radiol) 1991; 3: 37-40.
98. Charak BS, Gupta R, Mandrekar P, et al. Testicular dysfunction after cyclophosphamide-vincristine-procarbazine-prednisolone chemotherapy for advanced Hodgkin's disease. A long-term follow-up study. Cancer 1990; 65: 1903-1906.
99. Kreuser ED, Xiros N, Hetzel WD, Heimpel H. Reproductive and endocrine gonadal capacity in patients treated with COPP chemotherapy for Hodgkin's disease. J Cancer Res Clin Oncol 1987; 113: 260-266.
100. Tal R, Botchan A, Hauser R, Yogev L, Paz G, Yavetz H. Follow-up of sperm concentration and motility in patients with lymphoma. Hum Reprod 2000; 15: 1985-1988.
101. Kulkarni SS, Sastry PS, Saikia TK, Parikh PM, Gopal R, Advani SH. Gonadal function following ABVD therapy for Hodgkin's disease. Am J Clin Oncol 1997; 20: 354-357.
102. Kreuser ED, Felsenberg D, Behles C, et al. Long-term gonadal dysfunction and its impact on bone mineralization in patients following COPP/ABVD chemotherapy for Hodgkin's disease. Ann Oncol 1992; 3(Suppl 4): 105-110.
103. Radford JA, Clark S, Crowther D, Shalet SM. Male fertility after VAPEC-B chemotherapy for Hodgkin's disease and non-Hodgkin's lymphoma. Br J Cancer 1994; 69: 379-381.
104. Sieniawski M, Reineke T, Nogova L, et al. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood 2008; 111: 71-76.
105. Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J Clin Oncol 1995; 13: 1080-1088.
106. Bonadonna G, Bonfante V, Viviani S, Di RA, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 2004; 22: 2835-2841.
107. Ragni G, Lombardi C, Santoro A, Bestetti O, Wyssling H. Male infertility caused by the chemotherapy of Hodgkin's disease: MOPP versus ABVD. Acta Eur Fertil 1983; 14: 221-222.
108. Brusamolino E, Lunghi F, Orlandi E, et al. Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity. Haematologica 2000; 85: 1032-1039.
109. Hill M, Milan S, Cunningham D, et al. Evaluation of the efficacy of the VEEP regimen in adult Hodgkin's disease with assessment of gonadal and cardiac toxicity. J Clin Oncol 1995; 13: 387-395.
110. Horning SJ, Hoppe RT, Kaplan HS, Rosenberg SA. Female reproductive potential after treatment for Hodgkin's disease. N Engl J Med 1981; 304: 1377-1382.
111. Schilsky RL, Sherins RJ, Hubbard SM, Wesley MN, Young RC, DeVita VT. Long-term follow up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease. Am J Med 1981; 71: 552-556.
112. Andrieu JM, Ochoa-Molina ME. Menstrual cycle, pregnancies and offspring before and after MOPP therapy for Hodgkin's disease. Cancer 1983; 52: 435-438.
113. Henkelmann GC, Hagemeister FB, Fuller LM. Two cycles of MOPP and radiotherapy for stage III1A and stage III1B Hodgkin's disease. J Clin Oncol 1988; 6: 1293-1302.
114. Smardova L, Kral Z, Vasova I, Wagnerova B, Vorlicek J. Damage to ovarian functions in young women treated with ABVD and BEACOPP chemotherapy for Hodgkin's lymhoma. Ann Oncol 2005; 16: 118-119.
115. De Lena M, Ditonno P, Lorusso V, et al. Bulky mediastinal Hodgkin's disease: results of a combined modality approach (ABVD/MOPP alternating chemotherapy plus radiation therapy). Haematologica 1993; 78: 230-235.
116. Viviani S, Bonfante V, Ragni G, Bonadonna G, Valagussa P, Gianni AM. Fertility in young patients treated with chemotherapy for Hodgkin's disease (HD): Long-term results. J Clin Oncol (Meeting Abstracts) 2005; 23: 6578.
117. Lacher MJ, Toner K, Pregnancies and menstrual function before and after combined radiation (RT) and chemotherapy (TVPP) for Hodgkin's disease. Cancer Invest 1986; 4: 93-9100.
118. Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA, Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002; 20: 630-637.
119. Ismail-Khan R, Minton S, Cox C, et al. Preservation of ovarian function in young women treated with neoadjuvant chemotherapy for breast cancer: A randomized trial using the GnRH agonist (triptorelin) during chemotherapy. J Clin Oncol (Meeting Abstracts) 2008; 26: 524.
120. Azem F, Samara N, Cohen T, et al. Assessment of ovarian reserve following ovarian tissue banking and/or GnRH-a co-treatment prior to chemotherapy in patients with Hodgkin's disease. J Assist Reprod Genet 2008; 25: 535-538.
121. Huser M, Crha I, Ventruba P, et al. Prevention of ovarian function damage by a GnRH analogue during chemotherapy in Hodgkin lymphoma patients. Hum Reprod 2008; 23: 863-868.
122. Blumenfeld Z, Avivi I, Eckman A, Epelbaum R, Rowe JM, Dann EJ. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Fertil Steril 2008; 89: 166-173.
123. Castelo-Branco C, Nomdedeu B, Camus A, Mercadal S, Martinez de Osaba MJ, Balasch J. Use of gonadotropin-releasing hormone agonists in patients with Hodgkin's disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy. Fertil Steril 2007; 87: 702-705.
124. Blumenfeld Z, Eckman A. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a. J Natl Cancer Inst Monogr 2005; 2005: 40-43.
125. Dann EJ, Epelbaum R, Avivi I, et al. Fertility and ovarian function are preserved in women treated with an intensified regimen of cyclophosphamide, adriamycin, vincristine and prednisone (Mega-CHOP) for non-Hodgkin lymphoma. Hum Reprod 2005; 20: 2247-2249.
126. Marchesoni D, Driul L, Fruscalzo A, et al. Premature ovarian failure in patients affected by oncoematological disease. Minerva Ginecol 2005; 57: 545-550.
127. Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 2005; 52: 2761-2767.
128. Pereyra Pacheco, Mendez B, Ribas JM, et al. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecol Oncol 2001; 81: 391-397.
129. Blumenfeld Z, Shapiro D, Shteinberg M, Avivi I, Nahir M. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 2000; 9: 401-405.